Recently, a large number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants continuously emerged and posed a major threat to global public health. Among …

Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage. The receptor …

Abstract SARS-CoV-2 Omicron (B. 1.1. 529) BA. 4 and BA. 5 sub-lineages, first detected in
South Africa, have changes relative to Omicron BA. 1 including substitutions in the spike …

Omicron lineages BA. 4 and BA. 5 drove a fifth wave of COVID-19 cases in South Africa.
Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 …

ABSTRACT SARS-CoV-2 B. 1.1. 529.1 (Omicron BA. 1) emerged in November 2021 and
quickly became the predominant circulating SARS-CoV-2 variant globally. Omicron BA. 1 …

Abstract Although the SARS-CoV-2 Omicron variant (BA. 1) spread rapidly across the world
and effectively evaded immune responses, its viral fitness in cell and animal models was …

Abstract WHO-defined SARS-CoV-2 variants of concern (VOC) drive therapeutics and
vaccine development. The Omicron VOC is dominating the arena since November 2021, but …

Abstract Background Anti-Spike monoclonal antibodies represent one of the most tolerable
prophylaxis and therapies for COVID-19 in frail and immunocompromised patients …

Summary Background SARS-CoV-2 Omicron variant is rampantly spreading across the
globe. We assessed the pathogenicity and immune response generated by BA. 1.1 sub …